



OSTEOPOROSIS SCREENING & TREATMENT ALGORITHM



BISPHOSPHONATES

Benefits

Reduces risk of spine and hip fractures by 50% over 3 years

Risks

Hypocalcemia

Ocular inflammation

Esophageal inflammation

Atypical femer fracture

Osteonecrosis of jaw

If intolerance:

Denosumab

If contraindicated:

Denosumab

If GFR < 30:

Denosumab

DENOSUMAB

Benefits

Reduces incidence of verebral fractures by 68%

Reduces hip fractures by 40%

Reduces non-vertebral fractures by 20%

Risks

Hypocalcemia

Rare cases of acute remoral fracture and osteonecrosis of the jaw


Hypersensitivity reactions

Special considerations


Discontinuation associated with rapid bone loss: drug holiday not recommended

If treatment interrupted, alternate antiresorptive therapy sus as alendronate


CALCITONIN SALMON




ESTROGEN-RELATED THERAPIES





PARATHYROID HORMONE ANALOGS



SCLEROSTIN INHIBITOR





Reference

LeBoff, M.S., Greenspan, S.L., Insogna, K.L., Saag, K.G., Singer, A.J., & Siris, E.S. (2022). The clinician's guide to prevention and treatment of osteoporosis. *Osteoporosis International*, 33(10), 1-108.

<https://doi.org/10.1007/s00198-021-05900-y>